LB Pharmaceuticals

tenant

trial

Chronic Schizophrenia With Obsessive-Compulsive Symptoms: Comorbidity or a Subtype?

NCTId NCT00269464

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase — · Completed

Enrollment —

Sponsored by Sheba Medical Center

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Completed

Enrollment

—

Study type

Observational

Allocation

—

Model

—

Masking

—

Start

—

Primary completion

—

Eligibility

ALL · 18 Years · 65 Years

Interventions & indications

Drugs

—

Indications

Schizophrenia Schizophrenia Obsessive Compulsive Disorder Obsessive-Compulsive Disorder

Sponsors

Sheba Medical CenterLead Sponsor

Investigators

1

Joseph Zohar, MDPrincipal Investigator

Sites

0 total

Facts & assertions

2 sourced

Phase

NA

Status

COMPLETED

relationships

The graph out of here

lead_sponsor

Sheba Medical Center

company

indication

indication

indication

Obsessive Compulsive Disorder

indication

investigator

Joseph Zohar, MD

person